Skip to main content
. 2024 Feb 3;51(3):227–242. doi: 10.1007/s10928-023-09898-0

Fig. 6.

Fig. 6

Simulations of balovaptan dose-normalized exposure at steady state for 1.5 to 50.0 mg once-daily dosing. A Predicted dose-normalized PK profiles for a typical adult participant. B Distribution of simulated dose-normalized AUCss by dose for a neurotypical population (N = 1000). Solid and dashed horizontal lines indicate the dose-normalized median, and 5th and 95th percentiles of observed AUCss in an adult ASD population in VANILLA